NCT02170025 - Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

January 17, 2017

Study Completion Date

September 22, 2017

Conditions

Cystic Fibrosis

Interventions

DRUG

Riociguat (Adempas, BAY63-2521)

Participants received 0.5 mg BAY63-2521 three times daily (tid) for 14 days. The dose would be increased to 1 mg BAY63-2521 for an additional 14 days, if this was considered safe and tolerable on the basis of the available data for a given patient.

DRUG

Placebo

Participants received matching placebo tid.

Trial Locations (10)

1090

Bruxelles - Brussel

13353

Berlin

63110

St Louis

75674

Paris

80206

Denver

35233-1711

Birmingham

M5B 1W8

Toronto

3015 CE

Rotterdam

BT12 7AB

Belfast

SW3 6NP

London